Needham analyst Joseph Stringer has maintained their neutral stance on GILD stock, giving a Hold rating on February 3.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Joseph Stringer has given his Hold rating due to a combination of factors influencing Gilead Sciences’ performance. The company’s recent financial results showed a stronger-than-expected performance in their HIV franchise, particularly with Biktarvy sales surpassing expectations. Despite this, the initial revenue guidance for 2025 was somewhat conservative compared to previous estimates.
Stringer believes that while there is potential for growth with upcoming product launches and clinical updates, such as lenacapavir in HIV PrEP and Trodelvy in mTNBC, the current risk and reward balance justifies maintaining a Hold rating. He notes that although there are positive trends, including margin expansion and potential topline growth, the overall outlook remains cautious at the current stock levels.
According to TipRanks, Stringer is a 2-star analyst with an average return of 0.2% and a 38.17% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Vertex Pharmaceuticals, and Stoke Therapeutics.
In another report released on February 3, RBC Capital also maintained a Hold rating on the stock with a $84.00 price target.